bluebird bio
BLUE
$0.96
Share price
-4.04%
Change (1 day)
-74.81%
Change (1 year)
bluebird bio (BLUE) - Total liabilities
Total liabilities on the balance sheet as of September 2023 : $0.39 B
According to bluebird bio 's latest financial reports the company's total liabilities are $0.39 B. A company’s total liabilities is the sum of all current and non-current debts and obligations.
bluebird bio - Total liabilities on balance sheet (from 2012 to 2023)
Total liabilities by year
| Year | Total liabilities | Change |
|---|---|---|
| 2022-12-31 | $0.35 B | 63.34% |
| 2021-12-31 | $0.21 B | -48.49% |
| 2020-12-31 | $0.42 B | -3.67% |
| 2019-12-31 | $0.44 B | 23.66% |
| 2018-12-31 | $0.35 B | 29.1% |
| 2017-12-31 | $0.27 B | 11.44% |
| 2016-12-31 | $0.24 B | 63.78% |
| 2015-12-31 | $0.15 B | 131.88% |
| 2014-12-31 | $65.48 M | -9.96% |
| 2013-12-31 | $72.72 M | -41.85% |
| 2012-12-31 | $0.12 B | 44.38% |
| 2011-12-31 | $86.62 M |
Total liabilities for similar companies or competitors
| Company | Total liabilities | differencediff. | Country |
|---|---|---|---|
 Sanofi SNY | $57.61 B | 14,632.07% | 🇫🇷 France |
 Merck MRK | $65.42 B | 16,629.66% | 🇺🇸 USA |
 Sangamo Therapeutics
SGMO | $72.26 M | -81.52% | 🇺🇸 USA |
 GlycoMimetics
GLYC | $5.29 M | -98.65% | 🇺🇸 USA |
 BioMarin Pharmaceutical BMRN | $1.79 B | 359.98% | 🇺🇸 USA |